Sign Up
Stories
Alzheimer's Innovations: A Clinical Advance
Share
ADvantage Therapeutics Appoints Professo...
ALS Treatment Withdrawal: FDA Concerns
AMX0035 for PSP: Phase 3 Trial Commences
Overview
API
Biopharmaceutical innovations in Alzheimer's research have been recognized with significant awards, including BioArctic's LEQEMBI winning Best New Drug and Clinical Advance. Eisai and Biogen have presented promising results for the subcutaneous formulation of LEQEMBI, with potential for wider adoption. The companies plan to apply for U.S. approval by March 31, 2024, and are preparing for joint commercialization in the Nordics.
Ask a question
How might the joint commercialization of LEQEMBI in the Nordics impact the healthcare landscape and accessibility to Alzheimer's treatments?
How might the recognition of LEQEMBI at The Scrip Awards influence the perception and adoption of Alzheimer's treatments?
What are the potential implications of the subcutaneous formulation of LEQEMBI for patients with Alzheimer's?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
Jun 2023
Aug 2023
Oct 2023
Coverage